6
Clinical Trials associated with HSK-44459 / Not yet recruitingPhase 2 A Multicenter, Open-label Study to Evaluate the Long-term Safety and Efficacy of HSK44459 Tablets for the Treatment of Patients With Bechet's Disease
This is a long-term extension study of HSK44459-202 in eligible participants who have completed the Week 12 visit of the originating Study HSK44459-202. The total duration of this study will be up to 56 weeks which will include a 52-week treatment period, and a 4-week safety follow-up period after the last study intervention administration. Safety will be assessed by the incidence and severity of adverse events during the study.
A Phase 2 Study Investigating the Efficacy and Safety of HSK44459 Tablet Administered to Participants With Atopic Dermatitis
The purpose of this study is to assess the efficacy and safety of HSK44459 in adults with Atopic Dermatitis
HSK44459片在健康受试者中的安全性、耐受性、药代动力学的I期临床研究
[Translation] Phase I clinical study on the safety, tolerability and pharmacokinetics of HSK44459 tablets in healthy subjects
评价HSK44459片在健康受试者中单次和多次给药的安全性和耐受性;
[Translation] To evaluate the safety and tolerability of single and multiple doses of HSK44459 tablets in healthy subjects;
100 Clinical Results associated with HSK-44459
100 Translational Medicine associated with HSK-44459
100 Patents (Medical) associated with HSK-44459
100 Deals associated with HSK-44459